Vyndaqel Market, By Indication (Wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, wild-type), Hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, variant), and Transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP) ), By Strength ( 20 mg and 61 mg), By Payer (Public, Private, and Self-pay/Out-of-pocket), By Distribution Channel ( Hospital pharmacies, Specialty/Online pharmacies, and Retail pharmacies), By End User ( Hospitals, Cardiac Amyloidosis Centers, Ambulatory Surgical Centers, and Homecare Settings), By Age group ( Adults (≥18 yrs) and Elderly (≥65 yrs)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
선택하다 귀사의 비즈니스 요구 사항에 맞는 라이센스 유형
US$ 2,200
이천이백 달러
단일 사용자 라이센스
( 전체 보고서 )
US$ 4,500
US$ 3,000
Three thousand dollars
자주 구매되는 상품
다중 사용자 라이센스
(전체 보고서)
US$ 7,000
US$ 5,000
Five thousand dollars
기업 사용자 라이센스
(전체 보고서)
US$ 10,000
US$ 6000
Six thousand dollars
Client Testimonials
Client Testimonials
우리의 고객